TY - JOUR
T1 - Human milk oligosaccharides and infant gut microbiota
T2 - Molecular structures, utilization strategies and immune function
AU - Zhang, Bin
AU - Li, Long Qing
AU - Liu, Feitong
AU - Wu, Jian Yong
N1 - Funding Information:
This work was financially supported by the Hong Kong Scholar Program ( XJ2019049 ), The Hong Kong Polytechnic University , and the 111 Project ( B17018 ).
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2022/1/15
Y1 - 2022/1/15
N2 - Human milk oligosaccharides (HMOs) are a unique class of non-digestible carbohydrates present in the mother milk, which play a key role in the development of infant gut microbiota, epithelial barrier and immune function. The deficiency of HMOs in the bovine milk-based infant formula has been widely recognized as a major culprit for the much higher incidence of immune disorders of formula-fed infants. This report was to give an up-to-date review on the structure characteristics of HMOs and the possible mechanisms, and strategies for their cellular uptake, and metabolism by the gut bacteria and the associated effects on the infant gut microbiome, and immune function. Most previous studies have been carried out in animals or in vitro model systems on the utilization strategies for HMOs in infant bacteria and their roles in infant microbiome, and gut immune function. A few HMO molecules have been synthesized artificially and applied in infant formulas.
AB - Human milk oligosaccharides (HMOs) are a unique class of non-digestible carbohydrates present in the mother milk, which play a key role in the development of infant gut microbiota, epithelial barrier and immune function. The deficiency of HMOs in the bovine milk-based infant formula has been widely recognized as a major culprit for the much higher incidence of immune disorders of formula-fed infants. This report was to give an up-to-date review on the structure characteristics of HMOs and the possible mechanisms, and strategies for their cellular uptake, and metabolism by the gut bacteria and the associated effects on the infant gut microbiome, and immune function. Most previous studies have been carried out in animals or in vitro model systems on the utilization strategies for HMOs in infant bacteria and their roles in infant microbiome, and gut immune function. A few HMO molecules have been synthesized artificially and applied in infant formulas.
KW - Commercial applications
KW - Human milk oligosaccharides
KW - Immune functions
KW - Infant microbiota
KW - Utilization strategies
UR - http://www.scopus.com/inward/record.url?scp=85117132448&partnerID=8YFLogxK
U2 - 10.1016/j.carbpol.2021.118738
DO - 10.1016/j.carbpol.2021.118738
M3 - Journal article
C2 - 34823774
AN - SCOPUS:85117132448
SN - 0144-8617
VL - 276
JO - Carbohydrate Polymers
JF - Carbohydrate Polymers
M1 - 118738
ER -